Gonorrhea antibiotic resistance threat looms for gay/bisexual men
When other celebrities remain quiet out of fear of alienating their fanbase or impact- ing their net worth in the wake of anti-gay violence and repeated shootings of unarmed black men by police, Atlanta Dream point guard and lesbian Layshia Clarendon is as outspoken as ever.
Now in her first season with the Atlanta Dream after previously playing three seasons for the Indiana Fever, Clarendon describes herself as “biracial, black, gay, female, genderqueer and Christian.” She is also quickly adding activist to her list of identifiers. One scroll through her Twitter or Instagram feed and you’re likely to read her thoughts on feminism, white supremacy and the recent shooting of Alton Sterling, a black man whose final moments were captured on video as he was shot multiple times by police outside a convenience store in Baton Rouge, Louisiana.
“Woke to the news that yet another black man was murdered by the police. Another hashtag, another day, another injustice. #AltonSterling,” she tweeted on July 8. The Center for Disease Control and Prevention released their findings on July 14 in the Morbidity and Mortality Weekly Report on the growing threat of resistance to azithromycin, the antibiotic used to treat gonorrhea.
“The confluence of emerging drug resistance and very limited alternative options for treatment creates a perfect storm for future gonorrhea treatment failure in the U.S.,” said Jonathan Mermin, M.D., director of the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and Tuberculosis Prevention.
“History shows us that bacteria will find a way to outlast the antibiotics we’re using to treat it. We are running just one step ahead in order to preserve the remaining treatment option for as long as possible.”
The combination therapy currently recommended by CDC still works. To date, no treatment failures have been reported in the United States.
“It is unclear how long the combination therapy of azithromycin and ceftriaxone will be effective if the increases in resistance persist,” said Gail Bolan, M.D, director of CDC’s Division of STD Prevention. “We need to push forward on multiple fronts to ensure we can continue offering successful treatment to those who need it.”